Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: nitric oxide-donating therapies for eye disorders - NicOx

Drug Profile

Research programme: nitric oxide-donating therapies for eye disorders - NicOx

Alternative Names: NCX 1021; NCX 1653; NCX 422; NCX 434

Latest Information Update: 20 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NicOx
  • Class Antiglaucomas; Eye disorder therapies; Nitroso compounds
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Glaucoma; Ocular hypertension
  • Discontinued Diabetic macular oedema; Diabetic retinopathy

Most Recent Events

  • 20 Jul 2018 Discontinued - Preclinical for Diabetic macular oedema in France (Ophthalmic) (Nicox pipeline, July 2018)
  • 20 Jul 2018 Discontinued - Preclinical for Diabetic retinopathy in France (Ophthalmic) (Nicox pipeline, July 2018)
  • 28 Mar 2018 pSivida is now called EyePoint Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top